Sagimet Biosciences Inc. Payments to Acquire Marketable Securities
Sagimet Biosciences Inc. (SGMT) reported Payments to Acquire Marketable Securities of $46.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-11
- Sagimet Biosciences Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $39.90M, a 7.12% decline year-over-year.
- Sagimet Biosciences Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $6.75M, a 56.65% decline year-over-year.
- Sagimet Biosciences Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $17.08M, a 24.12% increase year-over-year.
- Sagimet Biosciences Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $31.26M, a 174.76% increase year-over-year.
- Sagimet Biosciences Inc. payments to acquire marketable securities for fiscal 2025 was $106.86M, a 1.13% decline from fiscal 2024.
- Sagimet Biosciences Inc. payments to acquire marketable securities for fiscal 2024 was $108.09M, a 450.90% increase from fiscal 2023.
- Sagimet Biosciences Inc. payments to acquire marketable securities for fiscal 2023 was $19.62M, a 52.66% decline from fiscal 2022.
- Sagimet Biosciences Inc. payments to acquire marketable securities for fiscal 2022 was $41.45M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $46.65M 10-Q · filed 2026-08-11 | $63.72M derived: sum of 3 quarters · filed 2026-08-11 | $94.98M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $6.75M 10-Q · filed 2026-05-12 | $23.83M derived: sum of 2 quarters · filed 2026-05-12 | $55.09M derived: sum of 3 quarters · filed 2026-05-12 | $98.04M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $17.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $48.34M derived: sum of 2 quarters · filed 2026-03-11 | $91.29M derived: sum of 3 quarters · filed 2026-08-11 | $106.86M 10-K · filed 2026-03-11 |
| 2025-09-30 | $31.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $74.21M derived: sum of 2 quarters · filed 2026-08-11 | $89.79M 10-Q · filed 2025-11-13 | $103.55M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $42.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $58.53M 10-Q · filed 2026-08-11 | $72.29M derived: sum of 3 quarters · filed 2026-08-11 | $83.66M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $15.57M 10-Q · filed 2026-05-12 | $29.33M derived: sum of 2 quarters · filed 2026-05-12 | $40.71M derived: sum of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | $13.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $25.14M derived: sum of 2 quarters · filed 2026-03-11 | $108.09M 10-K · filed 2026-03-11 | |
| 2024-09-30 | $11.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $94.33M 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $82.95M 10-Q · filed 2025-08-13 | |||
| 2023-12-31 | $19.62M 10-K · filed 2025-03-12 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $41.45M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $41.45M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $41.45M 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |